Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
linear decrease » linear increase (Expand Search)
decrease based » disease based (Expand Search)
mean decrease » a decrease (Expand Search)
Showing 341 - 360 results of 31,298 for search '(( significant decrease based ) OR ( significant ((linear decrease) OR (mean decrease)) ))', query time: 0.50s Refine Results
  1. 341
    Fig 2 -

    Fig 2 - by I. Moll (14227650)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  2. 342
    S2 File -

    S2 File - by I. Moll (14227650)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  3. 343
    S1 Data -

    S1 Data - by I. Moll (14227650)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  4. 344
    Details of the fatigue protocol.

    Details of the fatigue protocol. by I. Moll (14227650)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  5. 345
    Fig 3 -

    Fig 3 - by I. Moll (14227650)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  6. 346
    Example of a raw sEMG signal of the gastrocnemius muscle.

    Example of a raw sEMG signal of the gastrocnemius muscle. by I. Moll (14227650)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  7. 347
    DICER protein expression is significantly decreased in the absence of MOV10 and FMRP.

    DICER protein expression is significantly decreased in the absence of MOV10 and FMRP. by Monica C. Lannom (11772729)

    Published 2021
    Save to List
    Saved in:
  8. 348
    Transcriptional and translational markers of syncytialization and biochemical differentiation are significantly decreased by rotenone.

    Transcriptional and translational markers of syncytialization and biochemical differentiation are significantly decreased by rotenone. by O’Llenecia S. Walker (8486163)

    Published 2020
    Save to List
    Saved in:
  9. 349
    Scaling of overall health burden with yearly expenditure growth.

    Scaling of overall health burden with yearly expenditure growth. by Margherita Molaro (17803989)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 350
    Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Save to List
    Saved in:
  11. 351
    Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

    Published 2023
    Save to List
    Saved in:
  12. 352
    Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Save to List
    Saved in:
  13. 353
    Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Save to List
    Saved in:
  14. 354
    Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

    Published 2023
    Save to List
    Saved in:
  15. 355
    Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Save to List
    Saved in:
  16. 356
    Trends in the days of amoxicillin and amoxicillin-clavulanate therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of amoxicillin and amoxicillin-clavulanate therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Save to List
    Saved in:
  17. 357
    Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Save to List
    Saved in:
  18. 358
    Trends in the incidence of <i>Clostridioides difficile</i> infection (CDI) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of <i>Clostridioides difficile</i> infection (CDI) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phas... by Naoya Itoh (6029276)

    Published 2023
    Save to List
    Saved in:
  19. 359
    Trends in the incidence of extended-spectrum β-lactamase (ESBL)- producing Enterobacteriaceae per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of extended-spectrum β-lactamase (ESBL)- producing Enterobacteriaceae per 1000 patients, by month, during the pre-intervention period (Phase 1) and interven... by Naoya Itoh (6029276)

    Published 2023
    Save to List
    Saved in:
  20. 360
    Trends in the incidence of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional pe... by Naoya Itoh (6029276)

    Published 2023
    Save to List
    Saved in:

Search Tools: